Application of PRP-Exos in preparation of medicine for treating neuropathic pain

By using PRP-Exos to inhibit the TLR4/NF-κB signaling pathway, a drug composition was prepared for intrathecal injection, which solved the problem of limited efficacy of existing treatments for neuropathic pain and achieved effective reduction of inflammatory response and pain improvement.

CN121102275APending Publication Date: 2025-12-12ZHU XIANYI MEMORIAL HOSPITAL OF TIANJIN MEDICAL UNIV (TIANJIN MEDICAL UNIV METABOLIC DISEASE HOSPITAL TIANJIN METABOLIC DISEASE PREVENTION CENT)
1 Cites 0 Cited by

Patent Information

Application Number
CN202511666192.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-14
Publication Date
2025-12-12

AI Technical Summary

Technical Problem

Existing treatments for neuropathic pain have limited efficacy, and long-term use can easily lead to tolerance and adverse reactions. The mechanism of action of exosomes in neuropathic pain is unclear.

Method used

Platelet-rich plasma-derived exosomes (PRP-Exos) were used to reduce the expression of inflammatory factors in spinal cord tissue by inhibiting the TLR4/NF-κB signaling pathway, and were prepared into drug compositions for intrathecal injection, including analgesics and anti-inflammatory drugs.

Benefits of technology

It significantly reduces the inflammatory response caused by nerve damage, improves neuropathic pain symptoms, provides new ideas for clinical translation, overcomes the limitation of low bioavailability of peripheral drugs, and verifies the therapeutic effect through a multimodal evaluation system.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides application of PRP-Exos in preparation of a medicine for treating neuropathic pain, and relates to the technical field of clinical medicine. According to the invention, the treatment effect of PRP-Exos on neuropathic pain by inhibiting a TLR4 / NF-kappa B signal channel is clarified, a new thought is provided for clinical transformation, meanwhile, an intrathecal injection delivery mode is adopted, the limitation of low bioavailability of peripheral administration is overcome, meanwhile, the treatment effect is comprehensively verified through a behavioral-histological-molecular biological multi-modal evaluation system, and the application prospect is wide. The potential of the PRP-Exos in relieving the neuropathic pain is proved.
Need to check novelty before this filing date? Find Prior Art